Previous close | 12,026.00 |
Open | 12,070.00 |
Bid | 11,980.00 x 0 |
Ask | 11,984.00 x 0 |
Day's range | 11,882.00 - 12,144.00 |
52-week range | 9,461.00 - 12,186.00 |
Volume | |
Avg. volume | 2,953,990 |
Market cap | 185.842B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 36.89 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.28 (1.89%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.